The presently disclosed subject matter relates to a method for finding and identifying sites or regions on cancer cells that are not possessed by normal cells (neoantigens). The method comprises creation of xenoantibodies which are able to specifically bind to cancer cell specific sites, and do not bind to, or cross react with normal cells. These neoantigens are used to plan and create cancer treatments.
